Clinical trials: Bladder Cancer, completed
Bladder Cancer, Breast Cancer
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Conditions
- Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer
- Trial name
- NCT00014456
- Testing
- filgrastim, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Appendicitis, Evidence of Cholecystectomy
Point of Care 3D Ultrasound for Various Applications: A Pilot Study
Summary 1. Purpose and Objective: The purpose of this study is to test the feasibility of rapid acquisition of point of care 3D ultrasound in obtaining abdominal and/or pelvic images.
- Conditions
- Appendicitis, Evidence of Cholecystectomy, Gallstones, Pregnancy, Ectopic
- Trial name
- NCT02831556
- Where
- United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Duke University
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining SCH 66336 and gemcitabine may kill more tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00006351
- Testing
- gemcitabine hydrochloride, lonafarnib
- Where
- Netherlands
- Volunteers
- 34 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Bladder Cancer
A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer
To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with gross hematuria.
- Trial name
- NCT03193528
- Where
- 6 sites in United States, Japan
- Volunteers
- 450 people
- Sponsor
- Cedars-Sinai Medical Center
Sexual Dysfunction
Sexual Quality of Patients After Bladder Cancer Cystectomy
Bladder cancer is the second most prevalent urological cancer in France. About 1 in 5 new cases of bladder cancer infiltrate the muscles.
- Trial name
- QSCO (NCT04964895)
- Testing
- Questionnaires
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Toulouse
Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer
Arsenic Trioxide in Treating Patients With Urothelial Cancer
Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have recurrent cancer of the bladder or urinary tract.
- Conditions
- Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Transitional Cell Carcinoma of the Bladder, Ureter Cancer
- Trial name
- NCT00009867
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so…
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00053209
- Testing
- gemcitabine hydrochloride, pemetrexed disodium
- Where
- 121 sites in United States
- Volunteers
- 46 people
- Sponsor
- Eastern Cooperative Oncology Group
Muscle Invasive Bladder Cancer
Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer
Bladder cancer is the seventh cause of cancer mortality in France. Overall survival is poor, between 45 and 50% at 5 years. Optimal staging of lymph nodes and metastasis is crucial for treatment decision of muscle invasive…
- Trial name
- TEP-Vessie (NCT04053101)
- Testing
- PET CT
- Where
- 2 sites in France
- Volunteers
- 130 people
- Sponsor
- Institut Bergonié
Bladder Cancer
Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer
Intravesical treatment for superficial bladder cancer has been used for the past 4-5 decades. Intravesical chemotherapy is beneficial in terms of recurrence and time to recurrence in grade 1-2 stage Ta tumours, usually…
- Trial name
- BCG/EMDA-MMC (NCT01442519)
- Testing
- bacillus Calmette-Guerin, electromotive mitomycin
- Where
- Italy
- Volunteers
- 212 people
- Sponsor
- University of Rome Tor Vergata
Breast Cancer, Lung Cancer
Pillars4Life Trial
This study aims to explore whether cancer patients can benefit from completing the Pillars4Life online coping program. This randomized control trial will have half its subject completing the program and the other half receiving…
- Conditions
- Breast Cancer, Lung Cancer, Esophageal Cancer, Colon Cancer
- Trial name
- Pillars4Life (NCT02465892)
- Testing
- Pillars4Life
- Where
- United States
- Volunteers
- 284 people
- Sponsor
- Duke University
Bladder Cancer
PET/MRI and Biomarkers in Bladder Cancer
Muscle invasive bladder cancer is an aggressive malignancy. Currently the investigators lack accurate imaging technologies in clinical staging and estimation of response to neoadjuvant chemotherapy as well as prognostic…
- Trial name
- ACEBIB (NCT01918592)
- Testing
- MRI/acetate-PET imaging
- Where
- 3 sites in Finland
- Volunteers
- 25 people
- Sponsor
- Turku University Hospital
Bladder Tumors, Spinal Anesthesia
Magnesium vs. Dexmedetomidine in TURBT Under Spinal Anesthesia
This randomized controlled trial evaluated the effects of intraoperative intravenous magnesium sulfate versus dexmedetomidine on postoperative pain, analgesic consumption, hemodynamic stability, and respiratory function in…
- Conditions
- Bladder Tumors, Spinal Anesthesia, Postoperative Pain, Magnesium Sulfate
- Trial name
- TURBT (NCT07445451)
- Testing
- magnesium sulfate, Dexmedetomidine, Normal Saline
- Where
- Turkey (Türkiye)
- Volunteers
- 93 people
- Sponsor
- Dr. Lutfi Kirdar Kartal Training and Research Hospital
Bladder Cancer, Cervical Cancer
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
RATIONALE: Varenicline, the nicotine patch, and nicotine gum help people stop smoking. It is not yet known whether varenicline is more effective than the nicotine patch given together with nicotine gum in helping smokers quit…
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00790569
- Testing
- nicotine, varenicline
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- Butler Hospital
Prostate Cancer, Bladder Cancer
USPIO-enhanced and Diffusion-weighted MRI for the Detection of Pelvic Lymph Node Metastases
Preoperative detection of lymph node metastases in patients with prostate or bladder cancer is crucial for selection of the appropriate treatment strategy (surgery, androgen deprivation with/or without radiation therapy or…
- Trial name
- NCT00622973
- Testing
- Imaging: diffusion-weighted MRI, Sinerem (USPIO) enhanced MRI
- Where
- Switzerland
- Volunteers
- 130 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Bladder Cancer
MK-3475/BCG in High Risk Superficial Bladder Cancer
This is a single center Phase I safety and efficacy study of MK-3475 therapy used in combination with bladder infused BCG treatment for patients, 18 years or older, with high risk superficial bladder cancer (cancer not yet…
- Trial name
- MARC (NCT02324582)
- Testing
- Intravenous MK-3475/ Intravesical BCG
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Southern Illinois University
Bladder Cancer
Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer
The purpose of this study is to test the safety of avelumab and Bacille Calmette-Guerin (BCG) and see what effects (good and bad) that this combination treatment has on subjects with recurrent bladder cancer.
- Trial name
- OU-SCC-ABC (NCT03892642)
- Testing
- Avelumab, BCG
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Oklahoma
Recurrent Bladder Cancer
Celecoxib in Treating Patients With Bladder Cancer
This randomized phase IIb/III trial is studying celecoxib to see how well it works in preventing disease recurrence in patients who have bladder cancer.
- Trial name
- NCT00006124
- Testing
- celecoxib
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- National Cancer Institute (NCI)
Muscle Invasive Bladder Cancer
A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
This research study is studying a new anti-cancer drug durvalumab (MEDI4736) with or without another new anti-cancer drug Oleclumab (MEDI9447) before surgery for bladder cancer.
- Trial name
- NCT03773666
- Testing
- Durvalumab, Oleclumab
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Bladder Cancer
Hyperthermic Intra-Vesical Chemotherapy
The purpose of the HIVEC II trial is to find out if the combination of the new technology called hyperthermia (the use of heat) and a drug called mitomycin is more effective than mitomycin alone which is the standard treatment…
- Trial name
- HIVECII (NCT06768346)
- Testing
- Hyperthermia will be delivered in combination with each instillation using the Combat BRS system
- Where
- 14 sites in United Kingdom
- Volunteers
- 259 people
- Sponsor
- Queen Mary University of London
Advanced Malignancies
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein.
- Trial name
- NCT00948961
- Testing
- CDX-1401 in combination with Resiquimod and/or Poly-ICLC, CDX-1401, Resiquimod
- Where
- 7 sites in United States
- Volunteers
- 70 people
- Sponsor
- Celldex Therapeutics